which glp 1 agonists have cardiovascular benefit The effects of GLP-1 receptor beyond obesity and type 2 diabetes: An anti-atherosclerotic action Cardiovascular benefits of glucagon-like peptide-1
Description
Metabolism, 92 , 121135
However, substantial research is needed to expand their utility, optimize delivery methods, and improve patient outcomes
In the coming weeks, Novo Nordisk is expected to release fresh Phase III data for its next-generation weight loss treatment CagriSema, which analysts say could be the next big thing in the obesity space
The side effects are an open question and will get answered later
The decision to adjust dose based on heart rate should involve the overall clinical picture, not just one number in isolation
